AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X
[{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cynata Advances Planned Clinical Trial in Diabetic Foot Ulcers in MoU With TekCyte","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Cynata Therapeutics"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ethics Approval for Cynata\u2019s Clinical Trial in Diabetic Foot Ulcers","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Cynata Therapeutics"},{"orgOrder":0,"company":"MiMedx","sponsor":"MediWound","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces Collaboration with MIMEDX on EscharEx\u00ae Phase III Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"MiMedx"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innocan Pharma Announces Promising Successful Results in Efficacy Trial of Diabetic Foot Relief Treatment","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Innocan Pharma"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the collaboration, MIMEDX will provide its market leading placental tissue allograft EPIFIX® to be used during the wound healing phase of the EscharEx® (concentrate of proteolytic enzymes enriched in bromelain) Phase III study in venous leg ulcers (VLUs).

            Lead Product(s): Bromelain Enriched Proteolytic Enzyme,Dehydrated Human Amnion Membrane

            Therapeutic Area: Podiatry Product Name: EscharEx

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: MediWound

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration August 15, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Cannabidiol is a topical CB1 receptor negative allosteric modulator (NAM), which is being evaluated in phase 1 clinical studies for the treatment of Diabetic Foot.

            Lead Product(s): Cannabidiol

            Therapeutic Area: Podiatry Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 15, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            This will be the first clinical trial to utilise CYP-006TK, a polymer-coated silicon dressing (seeded with Cymerus MSCs) that Cynata has licensed from TekCyte Pty Ltd (TekCyte).

            Lead Product(s): Cymerus mesenchymal stem cells

            Therapeutic Area: Podiatry Product Name: CYP-006TK

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 30, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Cynata plans to undertake a clinical trial of its Cymerus MSC product in patients with diabetic foot ulcers based on this solid pre-clinical foundation and utilising the TekCyte technology.

            Lead Product(s): Cymerus mesenchymal stem cell

            Therapeutic Area: Podiatry Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 01, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY